NASDAQ:KDNY Chinook Therapeutics (KDNY) Stock Price, News & Analysis → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free KDNY Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$40.39▼$40.3950-Day Range$38.66▼$40.3952-Week Range$18.34▼$40.51VolumeN/AAverage Volume1.19 million shsMarket Capitalization$2.90 billionP/E RatioN/ADividend YieldN/APrice Target$37.25 Stock AnalysisStock Analysis Get Chinook Therapeutics alerts: Email Address Chinook Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.09 Rating ScoreUpside/Downside7.8% Downside$37.25 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.30) to ($3.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.04 out of 5 starsMedical Sector906th out of 908 stocksBiotechnology Industry22nd out of 22 stocks 1.0 Analyst's Opinion Consensus RatingChinook Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.09, and is based on 1 buy rating, 10 hold ratings, and no sell ratings.Amount of Analyst CoverageChinook Therapeutics has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for KDNY. Previous Next 0.0 Dividend Strength Dividend YieldChinook Therapeutics does not currently pay a dividend.Dividend GrowthChinook Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KDNY. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Chinook Therapeutics this week, compared to 1 article on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Chinook Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders16.79% of the stock of Chinook Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.15% of the stock of Chinook Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Chinook Therapeutics are expected to decrease in the coming year, from ($3.30) to ($3.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Chinook Therapeutics is -11.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Chinook Therapeutics is -11.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChinook Therapeutics has a P/B Ratio of 5.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Chinook Therapeutics Stock (NASDAQ:KDNY)Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.Read More Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> KDNY Stock News HeadlinesApril 21, 2024 | finance.yahoo.comThree Finalists Announced for the 2024 Bloom Burton AwardNovember 1, 2023 | usnews.comChinook ElementaryApril 26, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.August 8, 2023 | msn.comWedbush Downgrades Chinook Therapeutics (KDNY)August 2, 2023 | uk.finance.yahoo.comChinook Therapeutics, Inc. (KDNY)August 1, 2023 | markets.businessinsider.comExpert Ratings for Chinook TherapeuticsAugust 1, 2023 | msn.comWells Fargo Downgrades Chinook Therapeutics (KDNY)July 25, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KDNY, NETI, TALS, QUOTApril 26, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.July 16, 2023 | fool.comChinook Therapeutics (NASDAQ: KDNY)June 21, 2023 | seekingalpha.comChinook: Surprising Acquisition By Novartis, Deal Should Go ThroughJune 17, 2023 | finance.yahoo.comChinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) CongressJune 16, 2023 | benzinga.comMoore Kuehn Encourages NETI, SURF, KDNY, and NEX Investors to Contact Law FirmJune 14, 2023 | businesswire.comCHINOOK THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chinook ...June 13, 2023 | barrons.comKDNY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chinook Therapeutics, Inc. Is Fair to ShareholdersJune 13, 2023 | reuters.comNovartis buys Chinook for $3.5 bln in race to treat rare kidney diseaseJune 13, 2023 | markets.businessinsider.comWhy Are Chinook Therapeutics Shares Trading Higher TodayJune 12, 2023 | markets.businessinsider.comWhat 6 Analyst Ratings Have To Say About Chinook TherapeuticsJune 12, 2023 | finance.yahoo.comChinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) CongressJune 12, 2023 | seekingalpha.comNovartis Buys Chinook: M&A To Drive Future GrowthJune 12, 2023 | investorplace.comWhy Is Chinook Therapeutics (KDNY) Stock Up 58% Today?June 8, 2023 | markets.businessinsider.comChinook Shareholder Action ReminderMay 23, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM), Chinook Therapeutics (KDNY) and Zoetis (ZTS)May 21, 2023 | benzinga.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Chinook Therapeutics, Inc. - KDNYMay 21, 2023 | benzinga.comChinook Shareholder NoticeMay 19, 2023 | seekingalpha.comChinook Therapeutics: Travere's Pain Is Chinook's GainMay 19, 2023 | benzinga.comChinook Investor AlertSee More Headlines Receive KDNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chinook Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2023Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:KDNY CUSIPN/A CIK1435049 Webchinooktx.com Phone(206) 485-7241FaxN/AEmployees214Year FoundedN/APrice Target and Rating Average Stock Price Target$37.25 High Stock Price Target$42.00 Low Stock Price Target$32.00 Potential Upside/Downside-7.8%Consensus RatingHold Rating Score (0-4)2.09 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($3.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-187,870,000.00 Net Margins-4,199.93% Pretax Margin-4,115.56% Return on Equity-58.28% Return on Assets-44.72% Debt Debt-to-Equity RatioN/A Current Ratio5.82 Quick Ratio5.82 Sales & Book Value Annual Sales$6.13 million Price / Sales473.15 Cash FlowN/A Price / Cash FlowN/A Book Value$6.91 per share Price / Book5.85Miscellaneous Outstanding Shares71,810,000Free Float59,749,000Market Cap$2.90 billion OptionableOptionable Beta0.34 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Eric L. Dobmeier J.D. (Age 54)Pres, CEO & Director Comp: $972.19kMr. Tom Frohlich (Age 47)Chief Operating Officer Comp: $627.44kMr. Andrew James King D.V.M. (Age 43)Ph.D., Chief Scientific Officer Comp: $651.48kMr. Eric H. Bjerkholt M.B.A. (Age 63)Chief Financial Officer Ms. Sukhi ThethySr. VP of Fin. & AccountingMs. Noopur Batsha LiffickSr. VP of Investor Relations & Corp. CommunicationsMr. Kirk D. Schumacher J.D.Sr. VP & Gen. CounselMs. Jodi JamiesonSr. VP of HRDr. Alan Glicklich M.D. (Age 60)Exec. Officer Ms. Delphine Imbert Ph.D.Sr. VP of CMC & Technical OperationsMore ExecutivesKey Competitors89bioNASDAQ:ETNBBio-TechneNASDAQ:TECHArcellxNASDAQ:ACLXApogee TherapeuticsNASDAQ:APGEIDEAYA BiosciencesNASDAQ:IDYAView All CompetitorsInsidersAndrew James KingSold 1,168 sharesTotal: $45,587.04 ($39.03/share)William Mariner GreenmanSold 1,155 sharesTotal: $26,911.50 ($23.30/share) KDNY Stock Analysis - Frequently Asked Questions Should I buy or sell Chinook Therapeutics stock right now? 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chinook Therapeutics in the last twelve months. There are currently 10 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" KDNY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KDNY, but not buy additional shares or sell existing shares. View KDNY analyst ratings or view top-rated stocks. What is Chinook Therapeutics' stock price target for 2024? 11 brokerages have issued twelve-month price objectives for Chinook Therapeutics' shares. Their KDNY share price targets range from $32.00 to $42.00. On average, they predict the company's share price to reach $37.25 in the next twelve months. This suggests that the stock has a possible downside of 7.8%. View analysts price targets for KDNY or view top-rated stocks among Wall Street analysts. How were Chinook Therapeutics' earnings last quarter? Chinook Therapeutics, Inc. (NASDAQ:KDNY) announced its earnings results on Tuesday, May, 9th. The company reported ($0.85) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by $0.03. The firm earned $1.83 million during the quarter, compared to the consensus estimate of $0.14 million. Chinook Therapeutics had a negative trailing twelve-month return on equity of 58.28% and a negative net margin of 4,199.93%. Chinook Therapeutics's revenue for the quarter was down 32.2% on a year-over-year basis. What other stocks do shareholders of Chinook Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Chinook Therapeutics investors own include BioSyent (RX) and Continental Resources (CLR). This page (NASDAQ:KDNY) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchJeff Bezos Just Humiliated Elon MuskInvestorPlaceExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chinook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
